lead to new kinds of antibiotics
The recently emerged field of bacterial riboswitches may be a good hunting ground for effective targets against bacterial infection, according to a report by Yale researchers in the journal Chemistry and Biology.
Riboswitches are RNA elements that control gene expression in essential metabolic pathways. Researchers in the laboratory of Ronald R. Breaker, the Henry Ford II Professor of Molecular, Cellular and Developmental Biology, showed that a riboswitch controlling vitamin B1 (thiamine) levels is disrupted in the presence of pyrithiamine, a toxic compound related to the vitamin.
Bacteria and fungi fail to grow in pyrithiamine and become resistant by acquiring mutations in their riboswitches. This work, in combination with the recently solved crystal structures of purine riboswitches, opens a path to the directed design of drugs targeting riboswitches for use as antibiotics.
According to the researchers, it is inevitable that bacteria will evolve and that the drugs used to cure bacterial infections will eventually become ineffective. While it is often possible to alter existing drugs slightly, they suggest that a longer-term and more attractive solution is to create entirely new drugs that target bacteria in completely new ways. This approach would lengthen the useful clinical lifetime of a drug and make it possible to tackle resistant 'superbugs' with combinations of drugs, say the scientists.
The analog, pyrithiamine, was synthesized decades ago to study the then-new field of vitamin nutrition. It was quickly found to be toxic, but the mechanism was incompletely understood. Breaker and his co-workers show that pyrithiamine is metabolized and binds to the riboswitch controlling thiamine.
Co-authors at Yale on the work are Narasimhan Sudarsan, Smadar Cohen-Chalamish, Shingo Nakamura and Gail Mitchell Emilsson. The study was funded by the Defense Advanced Research Projects Agency, National Institutes of Health, and the David and Lucile Packard Foundation.
Breaker, a Howard Hughes Medical Institute investigator, is co-founder of BioRelix, a company pursuing licensing of intellectual property related to riboswitches.
-- By Janet Rettig Emanuel
T H I S
W E E K ' SS T O R I E S
Three alumni named Yale trustees
NAS honors researchers' work in molecular biology, psychology
Building Yale ties in the Middle East
CPTV show looks at creation of Torosaurus
ENDOWED PROFESSORSHIPS
Koichi Hamada designated the Tuntex Professor of Economics
Daniel Harrison named the Allen Forte Professor of Music Theory
Mark R. Rosenzweig appointed Altschul Professor of . . . Economics
Craig M. Wright designated . . . Moses Professor of MusicU.S. lags in ranking of nations' environmental performance
Grants support project to make scientific literature available . . .
New alliance to foster university collaborations
Exhibit features abstract scenes of London by John Virtue
Smaller paintings by John Virtue will be on view at JE College
Study finds no link between soda consumption, esophageal cancer
F&ES makes progress on efforts to become more 'green'
Lab's research on riboswitches may lead to new kinds of antibiotics
Team's research shows that stress in infancy . . .
Alumnae's artwork depicts Yale 'Encounters and Memories'
LIBRARY NEWS
Staff's quick work helped minimize flood damage
New Orbis features include ability for 'wildcard' searchMichael Wallerstein, noted research scholar on economic equality
Symposium will look at the use of new materials in modern sculpture
Bockenstedt named director of professional development at medical school
Yale nurse devoted to HIV/AIDS treatment and education in China . . .
Campus Notes
Bulletin Home|Visiting on Campus|Calendar of Events|In the News
Bulletin Board|Classified Ads|Search Archives|Deadlines
Bulletin Staff|Public Affairs|News Releases|
E-Mail Us|Yale Home